3rd Dec 2018 09:05
LONDON (Alliance News) - FTSE 250-listed healthcare-focused investor Syncona Ltd on Monday reported on progress made by portfolio company, Nasdaq-listed Autolus Therapeutics Inc, on its developmental therapies.
Autolus has dosed its first patient in is Phase 1/2 LibrA T1 clinical trial of Auto4, a developmental therapy for the treatment of T cell receptor beta chain 1-positive peripheral T cell lymphoma.
In addition, data from its sister program, AUTO5 which is targeting TRBC2-positive lymphoma, were presented at the 60th American Society of Hematology Annual Meeting in San Diego.
Autolus T cell program is made of a companion diagnostic to identify whether positive peripheral T cell lymphoma is TRBC1- or TRBC2-positive, and the two T cell product candidates AUTO4 and AUTO5.
Positive peripheral T cell lymphoma is a rare form of non-Hodgkin lymphoma, the most commonly occurring blood cancer where cells of the immune system called lymphocytes grow and multiply uncontrollably.
In addition, Autolus presented its initial results from its phase 1/2 clinical trials for AUTO3, designed to treat paediatric acute lymphoblastic leukaemia and diffuse large B cell lymphoma.
The AMELIA trial, which tests AUTO3's safety and efficacy when used to treat lymphoblastic leukaemia, indicated that AUTO3 has a manageable safety profile, with the potential to overcome target negative relapse, currently a limitation in many therapies targeting CD19.
CD19 is a transmembrane protein used as a biomarker for lymphocyte development and as a target for leukaemia immunotherapies.
The ALEXANDER trial, testing for the treatment's safety when used for B cell lymphoma, indicated that AUTO3 has a manageable safety profile at the currently evaluated doses.
Shares in Syncona were up 1.2% at 267.65 pence on Monday.
Related Shares:
Syncona